Navigation Links
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
Date:10/25/2007

in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite that is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013   Lexicon ... a biopharmaceutical company focused on discovering breakthrough treatments ... Northcott has joined the company as its ... Mr. Northcott brings extensive commercial experience to Lexicon, ... a variety of therapeutic areas. Mr. ...
(Date:6/18/2013)... 18, 2013 Though health care jobs ... to the U.S. Bureau of Labor Statistics -- the increase ... per month. Most new health care jobs were added in ... saw a loss of 6,000 jobs. Overall, the U.S. unemployment ... Challenger, Gray & Christmas reported that a total of just ...
(Date:6/18/2013)... PathoGenetix, Inc. , a ... bacterial strain typing, announced today that John A. ... Vice President of Engineering. Dr. Luckey will lead ... RESOLUTION™ Microbial Genotyping System . The fully automated ... assay kits, database and software, will be commercially ...
(Date:6/18/2013)... On June 11, 2013 the Centers for Medicare ... memorandum concluding that FDG Position Emission Tomography (PET) is ... strategy, and the agency ended the requirement for ... was developed jointly by the ACR and WMIS as ... Evidence Development (CED) program to determine if FDG-PET scans ...
Breaking Biology Technology:John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 2PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 3WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3
... ... management solutions. The company was approved for $250,000 for completion and commercialization of their ... the sensor™.” , ... (Vocus) April 30, 2010 -- Smartfield, Inc. is an information ...
... HEALTHeCAREERS Network , North America ,s leading healthcare-employment ... , , ... , , ... Interventions (SCAI) recently joined the Network, launching the SCAI Career Center ...
... April 29, 2010 At the 10th Congress ... Monaco on March,12-13, 2010 , Professor ... Euro,PDT, described the current state of topical photodynamic therapy, a,revolutionary ... underscored the major role played by the Euro PDT, whose,objective ...
Cached Biology Technology:$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3Therapeutic Revolution in Dermatology 2Therapeutic Revolution in Dermatology 3Therapeutic Revolution in Dermatology 4
(Date:6/17/2013)... Bethesda, MD (June 17, 2013) The AGA Research ... advancing in the future of gastroenterology with the 2013 ... Pharma Student Abstract Prizes. , "In its third year, ... researchers who are embarking on promising careers in basic ... chair of the AGA Research Foundation. "We are extremely ...
(Date:6/17/2013)... mining shale gas, is widespread across Pennsylvania, covering up ... in the Annals of the New York Academy ... including pollution from toxic chemicals, the building of well ... gas has engendered a great deal of controversy, largely ... on biological diversity and resources have scarcely been addressed ...
(Date:6/16/2013)... 16, 2013)Male mice who were fed a high-fat diet ... who also had higher levels of body fat, a ... observed primarily in male offspring, despite their consumption of ... meeting of The Endocrine Society in San Francisco, Calif. ... affect metabolism and behavior of offspring dependent on the ...
Breaking Biology News(10 mins):Horizon Pharma Abstract Prizes recognize promising fellows and students 2Obese male mice father offspring with higher levels of body fat 2
... the winter of 2005-2006 occurred at the edge of ... and the Erasmus Medical Centre, Rotterdam, the Netherlands. Their ... PLoS Pathogens, show that these outbreaks were driven ... of frozen water. The researchers found that most ...
... N.Y. (April 8, 2010) Autism Speaks, the world,s ... awarding of 16 new research grants totaling $5,223,743 over ... span basic research, which provides the innovative discoveries that ... neuroscience research, which further develops these discoveries in animal ...
... April 8, 2010 Researchers have shown that a peptide ... penetrate deeply into tumor tissue. The peptide has been shown ... pancreatic cancers in mice, achieving the same therapeutic effect as ... In a transformative paper published today in the online edition ...
Cached Biology News:Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years 2Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years 3Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years 4Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years 5Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years 6Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years 7Cancer drug effectiveness substantially advanced 2